Clinical Trial

P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation

Study acronym: FOLLOW-AF
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide and is associated with substantial morbidity, mortality, and healthcare utilization. Catheter ablation, most commonly pulmonary vein isolation (PVI), is an established rhythm control strategy for AF4. Despite technological advances and the emergence of pulse field ablation (PFA), long-term AF recurrence after a first ablation procedure remains frequent, occurring in approximately 30-50% of patients5. Post-ablation follow-up strategies, including visit frequency, rhythm monitoring intensity, and Antiarrhythmic Drug management, vary widely across providers and institutions and are largely guided by subjective assessment rather than objective, science-based recurrence risk estimation6. In parallel, asymptomatic (silent) AF recurrence is exacerbated following ablation, limiting the reliability of symptom-driven follow-up7. FOLLOW-AF is a retrospective, observational cohort study designed to validate the FollowGenius algorithm and evaluate the diagnostic performance in predicting AF recurrence based on atrial remodeling and vein isolation. The cohort will be patients with paroxysmal or persistent AF who underwent PVI with the PFA modality.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-06 -> 2026-08-31 2026-08-13
minor Completion pushed: 2026-08 -> 2026-09-15 2026-08-13
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-05-16
Trial Details
NCT Number NCT07471308
Lead Sponsor CathVision ApS
Conditions Atrial Fibrillation (AF), Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, Atrial Fibrillation (Paroxysmal), Pulmonary Vein Isolation
Enrollment 300 participants
Start Date 2026-04-13
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-12